Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Clinical and Experimental Medicine

• Publication date

  2015-09-15

• Fields of study

  Medicine

• Identifiers
  PMID 26629188PMCID PMC4659076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer survival in China, 2003–2005: A population‐based study

  2015cited by this paper
• Polymorphism of costimulatory molecules (CTLA4, ICOS, PD.1 and CD28) and allogeneic hematopoietic stem cell transplantation in Iranian patients

  2014cited by this paper
• PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer.

  2014cited by this paper
• Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

  2014cited by this paper
• Association between single nucleotide polymorphism of PD‐L1 gene and non‐small cell lung cancer susceptibility in a Chinese population

  2014cited by this paper
• CTLA-4 (+49A/G) Polymorphism and Type-1 Diabetes in Turkish Children

  2013cited by this paper
• Association between polymorphisms in PDCD1 gene and aplastic anemia in Chinese Han population

  2013cited by this paper
• CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Association of genetic variation in co-stimulatory molecule genes with outcome of liver transplant in Iranian patients.

  2012cited by this paper
• CTLA-4 +49A>G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis

  2011cited by this paper
• CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer.

  2011cited by this paper
• T cell costimulation and coinhibition: genetics and disease.

  2011cited by this paper
• Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility.

  2009cited by this paper
• DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

  2009cited by this paper
• [The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines.].

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.

  2008cited by this paper
• Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.

  2008cited by this paper
• Non-small cell lung cancer staging: proposed revisions to the TNM system

  2008cited by this paper
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

  2007cited by this paper
• PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children

  2007cited by this paper
• Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.

  2006cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes.

  2003cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Concomitant Administration of Interleukin‐2 Plus Tumor Necrosis Factor in Advanced Non‐Small Cell Lung Cancer

  1995cited by this paper
• Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer

  1992cited by this paper
• Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.

  1992cited by this paper
• Long-term results in combined-modality treatment of small cell carcinoma of the lung.

  1978cited by this paper

• Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond.

  2025cites this paper
• CTLA4 genetic variants influence immune regulation and susceptibility of HPV associated cervical cancer

  2025cites this paper
• PDCD1 gene single nucleotide polymorphisms and haplotypes are associated with higher risk of breast cancer development.

  2025cites this paper
• Possible Associations between PD1/PDL1 Gene Variants, Gene Expression, and Protein Expression and Clinical Outcome of Non-Small-Cell Lung Cancer.

  2025cites this paper
• Association of PD-1 immune checkpoint polymorphisms with oral cancer risk: results from a Pakistani case-control study

  2025cites this paper
• Programmed Death Receptor 1 Gene Polymorphisms Influence the Occurrence of Recurrent Pregnancy Loss among Iraqi Women

  2025cites this paper
• Association between cytotoxic T-lymphocyte antigen-4 polymorphisms and lung cancer susceptibility: Evidence from a meta-analysis

  2025cites this paper
• Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies

  2024cites this paper
• Investigation of PD-1 gene variants in patients with endometrial cancer: A case-control study

  2024cites this paper
• Immunomodulatory gene polymorphisms in non-small cell lung carcinoma susceptibility and survival

  2024influential citation
• rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

  2024cites this paper
• The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma

  2023cites this paper
• Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma

  2023cites this paper
• CTLA‐4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer

  2022cites this paper
• Haplotyping of PD-1 Polymorphisms in Egyptian Patients with Colorectal Cancer: A Case-Control Study.

  2022cites this paper
• PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients

  2022cites this paper
• PD-L1 rs2890658 Polymorphism Increases Risk for Non-Small-Cell Lung Cancer in Northern China Population Based on Experimental Data and Meta-Analysis

  2022cites this paper
• Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk

  2022cites this paper
• Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis

  2022cites this paper
• Liquid biopsy in targeting gene polymorphism related to the response within immunocheckpoint inhibitors therapeutic regimen

  2021cites this paper
• Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk

  2021cites this paper
• Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome

  2021cites this paper
• CTLA-4 +49 A/G Polymorphism and the Risk of Lung Cancer: a Meta-analysis

  2021cites this paper
• Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma

  2021influential citation
• PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

  2021cites this paper
• Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects

  2021cites this paper
• PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

  2021cites this paper
• Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers

  2021cites this paper
• Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women

  2020influential citation
• The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population.

  2020cites this paper
• The role of genetic polymorphism within PD-L1 gene in cancer. Review.

  2020cites this paper
• Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers.

  2020cites this paper
• PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population

  2020cites this paper
• Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

  2019cites this paper
• PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.

  2019cites this paper
• Association of cytotoxic T‐lymphocyte associated protein 4 gene polymorphisms with the risk and prognosis of oesophageal cancer in a high‐incidence region from northern China

  2019cites this paper
• Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.

  2019cites this paper
• Title Clinical Impact of Single Nucleotide Polymorphism in PD-L 1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

  2019cites this paper
• Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

  2019cites this paper
• PD-1 and cancer: molecular mechanisms and polymorphisms

  2018cites this paper
• The effects of Tim-3 activation on T-cells in gastric cancer progression

  2018cites this paper
• Immunopharmacogenomics in Cancer Management

  2018cites this paper
• PD-1 Haplotype Combinations and Susceptibility of Patients to Squamous Cell Carcinomas of Head and Neck

  2018influential citation
• The PD-1 rs36084323 A > G polymorphism decrease cancer risk in Asian: A meta-analysis.

  2018cites this paper
• Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

  2018cites this paper
• Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

  2017cites this paper
• The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.

  2017cites this paper
• Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers

  2017cites this paper
• Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients

  2017cites this paper
• Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study

  2016cites this paper
• Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma.

  2016cites this paper
• Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies

  2016cites this paper
• A PRISMA-compliant meta-analysis

  2016influential citation